Since its discovery in the early 1980s, the transforming growth factor ␤ (TGF-␤) family has been profoundly implicated in many aspects of cell and developmental biology (11) . The signaling activity of TGF-␤ is under intricate regulation. During embryonic development this is critical for spatial and temporal control of tissue patterning. In adult tissues, balanced TGF-␤ pathway activity is important for homeostasis. A loss of TGF-␤ tumor suppressor function is a hallmark of cancers (6) . On the other hand, excessive TGF-␤ signaling is recognized as a major contributor to fibrosis of the heart, lung, and liver (10) . Therefore, elucidating the molecular mechanisms fine-tuning TGF-␤ signaling activity is an important part of understanding the biological impact of TGF-␤ in development and diseases. In this issue, Yan and colleagues report the novel finding that the molecule TSC-22 (TGF-␤-stimulated clone 22), whose gene has long been known as a TGF-␤ target (8) , serves to enhance TGF-␤ signaling (12) . This is the first clear case of feed forward mechanism in the TGF-␤ signal transduction pathway.
Negative feedback control of TGF-␤ signaling by Smad7. The TGF-␤ signal is transduced into the nucleus by the Smad family of intracellular proteins (7) . In cells receiving TGF-␤ treatment, Smad2 and Smad3 (Smad2/3) become phosphorylated in their carboxyl termini. This phosphorylation event is catalyzed by the ligand-bound TGF-␤ receptor kinases, which form a complex that consists of type I and type II receptors (T␤RI and T␤RII). The carboxy-terminal phosphorylation is a prerequisite for Smad2/3 to enter the nucleus and regulate the expression of many genes that underlie the biological responses to TGF-␤. Smad2/3 stay phosphorylated only transiently even though TGF-␤ association with the receptor complex is highly stable. The dynamics of Smad2/3 phosphorylation also varies in different cell types. All these hint at intracellular mechanisms that modulate the duration of Smad phosphorylation/activation. In the late 1990s, when the Smad family was characterized, two members of the family, Smad6 and Smad7, appeared to act as inhibitors that attenuate TGF-␤ signaling (2) . Smad7, the one that received more attention, was found to physically interact with the T␤RI/T␤RII complex and prevent Smad2/3 activation by blocking the access of Smad2/3 to the receptor kinases and by recruiting the ubiquitin ligase Smurf for the destruction of the receptor kinase (2) . Importantly, from Drosophila to vertebrates, the Smad7 gene is an immediate early gene target of TGF-␤ and its transcription is directly activated by Smad2/3, so this is a highly conserved negative feedback mechanism that keeps TGF-␤/Smad signaling in check. Yan et al. now add an interesting twist to this paradigm by showing that TSC-22 acts to specifically alleviate the negative impact of Smad7 on Smad2/3 activation ( Fig. 1) .
A positive feedback mechanism by TSC-22. The TSC-22 gene was found many years ago to be a target gene of TGF-␤, but its potential connection to TGF-␤ signaling was not fully explored until Yan et al. discovered the TSC-22 interaction with T␤RI in a yeast two-hybrid screen (12) . All functional assays point to a positive role for TSC-22 in facilitating Smad phosphorylation in response to TGF-␤. The exact biochemical function of TSC-22 has been elusive; it harbors a leucine zipper domain and resides mostly in the cytoplasm, so how it may enhance Smad phosphorylation was intriguing. An important clue came from the realization that the pro-TGF-␤ activity of TSC-22 was lost in Smad7 Ϫ/Ϫ mouse embryonic fibroblasts (MEF) or when the Smurf ubiquitin ligase was depleted by RNA interference (RNAi) (12) . Thus, mitigating Smad7 activity appears to be the main function of TSC-22. Indeed, overexpression of TSC-22 effectively reduced Smad7-TGF-␤ receptor interaction and consequently protected TGF-␤ receptor kinase from ubiquitination and degradation. The physiological relevance of this finding was supported by observations in a rat myocardiac fibrosis model. Upon induction of fibrosis by isoproterenol injection, there was a clear elevation of TGF-␤ signaling and concomitantly an increased TSC-22 expression. In primary cardiac fibroblasts, RNAi knockdown of TSC-22 resulted in diminished TGF-␤ induction of fibrosis-related genes including the plasminogen activator inhibitor 1 (PAI-1) and ␣-smooth muscle antigen (␣-SMA) genes. Therefore, this feed forward mechanism may play a role in achieving a high and sustained level of TGF-␤ signaling activity that drives tissue fibrosis.
TSC-22 has four homologs in mammals, each with a highly conserved leucine zipper motif and a TSC box. Interestingly, the Smad7 interaction domain in TSC-22 was mapped to the N terminus, which is divergent among the TSC family members, suggesting that the pro-TGF-␤ activity is unique to TSC-22. However, the molecular details of how TSC-22 interrupts the Smad7/TGF-␤ receptor interaction are still murky. An excessive amount of TSC-22 can compete away Smad7, but it is unclear whether TSC-22 and Smad7 simply compete for the same interaction interface on the receptor complex. At the sequence level TSC-22 and Smad7 share little resemblance, but one cannot rule out the possibility that there is similarity between the two in higher-order structures. On the other hand, it may also be possible that TSC-22 and Smad7 bind to different domains in T␤RI and that an allosteric effect prevents them from interacting simultaneously with T␤RI. At present, it is not known whether T␤RI has a higher affinity for TSC-22 than Smad7. More interestingly, Yan et al. detected TSC-22 interaction with T␤RI 15 min after TGF-␤ stimulation, while the Smad7/T␤RI association was observed at a later time point (12) . This seems to argue that TSC-22 is a favored binding partner of the receptor kinases and serves as a protective shield that prevents Smad7/Smurf-mediated degradation of T␤RI. Why the T␤RI/T␤RII complex prefers TSC-22 for initial interaction remains to be determined. Important answers may come from biochemical and biophysical analysis of T␤RI/ T␤RII interaction with Smad7 and TSC-22. It is also possible that differences in subcellular localization or the dynamics of intracellular movement of TSC-22 and Smad7 may contribute to the more rapid association between the former and T␤RI upon ligand stimulation.
Biological implications. As exemplified in other signaling pathways, transient versus sustained TGF-␤ signaling may give rise to distinct biological outcomes. So it is conceivable that the balancing act of TSC-22 and Smad7 is an important determinant of the nature of TGF-␤ responses. Future genetic studies in mice or model organisms may shed light on the biological significance of TSC-22 in the many processes regulated by TGF-␤. In this regard, it has been reported that ablation of the TSC-22 gene in mice did not result in any severe phenotypes other than a higher proliferation rate of hematopoietic precursor cells (HPCs) (13) . TGF-␤ is a potent regulator of several hematopoietic cell lineages in terms of proliferation and cell fate determination (4) . So this phenotype may be partly attributable to reduced TGF-␤ signaling. The removal of TSC-22 did not appear to affect embryonic development in general, arguing against a role for TSC-22 in general TGF-␤ signaling, although one cannot rule out compensatory mechanisms. On the other hand, it is also possible that TSC-22 may significantly impact TGF-␤ responses only upon pathophysiological perturbations such as during fibrosis. In this regard, the TSC-22
mouse provides a convenient model to study whether experimentally induced fibrosis is weaker in the absence of TSC-22.
On the surface, given the opposite effects of TSC-22 and Smad7 on TGF-␤ signaling, it may seem self-defeating that both are induced by TGF-␤. Thus, the dynamics of TSC-22 and Smad7 induction and their relative protein levels upon TGF-␤ stimulation become critical issues. The authors mentioned in passing that the Smad7 gene appears to be transcriptionally activated by TGF-␤ more rapidly than the TSC-22 gene is, which suggests that TSC-22 might be more important for those genes whose expression requires sustained TGF-␤ input. More importantly, previous studies have shown that TSC-22 expression is also regulated by other factors such as androgen (9) . The level of TSC-22 is suppressed in a number of cancers such as prostate cancer, leukemia, and salivary gland cancer through mechanisms that are not well characterized. Therefore, TSC-22 may provide an entry point for multiple signals and pathways to set a tone for the level of TGF-␤ signaling.
Summary. Previous studies have identified many players that influence the level and duration of TGF-␤ signaling besides Smad7 and Smurf. Examples include extracellular factors that control the availability of bioactive TGF-␤ ligands (14) , Smad C-terminal phosphatases that deactivate Smad (5), Ste20 kinases that phosphorylate Smad in ␣-helix 1 and prevent C-terminal phosphorylation (3), and cyclindependent kinase (CDK) and mitogen-activated protein kinase (MAPK), which phosphorylate the Smad linker region and induce its degradation (1) . All of these processes are mechanisms that turn off TGF-␤ signaling, so the discovery of a feed forward mechanism that reinforces TGF-␤ signaling is an important advance in the field. Much remains to be further investigated, perhaps the most important being the biological impact of TSC-22 in TGF-␤-regulated cellular processes.
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